Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection

Abstract The aim of this study was to evaluate the efficacy and safety of outpatient antimicrobial therapy with piperacillin-tazobactam in continuous infusion using elastomeric pumps and to evaluate the economic impact compared with conventional hospital treatment in patients with Pseudomonas aerugi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jose Luis Lamas Ferreiro, Judith Álvarez Otero, Ana Sanjurjo Rivo, Lucía González González, Irene Rodríguez Conde, María Fernández Soneira, Javier Posada García, Javier de la Fuente Aguado
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2e67001240094fa9a004bb7c9c0b0b1a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2e67001240094fa9a004bb7c9c0b0b1a
record_format	dspace
spelling	oai:doaj.org-article:2e67001240094fa9a004bb7c9c0b0b1a2021-12-02T17:32:59ZOutpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection10.1038/s41598-021-88179-72045-2322https://doaj.org/article/2e67001240094fa9a004bb7c9c0b0b1a2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88179-7https://doaj.org/toc/2045-2322Abstract The aim of this study was to evaluate the efficacy and safety of outpatient antimicrobial therapy with piperacillin-tazobactam in continuous infusion using elastomeric pumps and to evaluate the economic impact compared with conventional hospital treatment in patients with Pseudomonas aeruginosa (PA) infections. This is an observational study. Patients with PA infection treated with continuous piperacillin-tazobactam infusion using elastomeric pumps in our hospital between January 2015 and December 2017 were included. Primary outcomes were mortality during antibiotic treatment and mortality at 30 days. Secondary outcomes were reinfection or relapse at 30 days and clinical cure rate. The cost of each episode was compared with theoretical cost of the same treatment using conventional hospitalization. 35 patients were included. One patient (2.9%) died during the treatment. Overall 30-day mortality was 5.7%. No death was related to infection by PA. One patient (2.9%) had a reinfection at 30 days. Cure was achieved in 93% of patients at the end of treatment. There were no severe complications related to elastomeric pumps. Treatment cost with outpatient antimicrobial therapy was 67% lower than theoretical cost with conventional hospital treatment. Oupatient antimicrobial therapy with piperacillin-tazobactam in continuous infusion using elastomeric pumps in patients with PA infections is safe and effective with lower costs.Jose Luis Lamas FerreiroJudith Álvarez OteroAna Sanjurjo RivoLucía González GonzálezIrene Rodríguez CondeMaría Fernández SoneiraJavier Posada GarcíaJavier de la Fuente AguadoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-4 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jose Luis Lamas Ferreiro Judith Álvarez Otero Ana Sanjurjo Rivo Lucía González González Irene Rodríguez Conde María Fernández Soneira Javier Posada García Javier de la Fuente Aguado Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection
description	Abstract The aim of this study was to evaluate the efficacy and safety of outpatient antimicrobial therapy with piperacillin-tazobactam in continuous infusion using elastomeric pumps and to evaluate the economic impact compared with conventional hospital treatment in patients with Pseudomonas aeruginosa (PA) infections. This is an observational study. Patients with PA infection treated with continuous piperacillin-tazobactam infusion using elastomeric pumps in our hospital between January 2015 and December 2017 were included. Primary outcomes were mortality during antibiotic treatment and mortality at 30 days. Secondary outcomes were reinfection or relapse at 30 days and clinical cure rate. The cost of each episode was compared with theoretical cost of the same treatment using conventional hospitalization. 35 patients were included. One patient (2.9%) died during the treatment. Overall 30-day mortality was 5.7%. No death was related to infection by PA. One patient (2.9%) had a reinfection at 30 days. Cure was achieved in 93% of patients at the end of treatment. There were no severe complications related to elastomeric pumps. Treatment cost with outpatient antimicrobial therapy was 67% lower than theoretical cost with conventional hospital treatment. Oupatient antimicrobial therapy with piperacillin-tazobactam in continuous infusion using elastomeric pumps in patients with PA infections is safe and effective with lower costs.
format	article
author	Jose Luis Lamas Ferreiro Judith Álvarez Otero Ana Sanjurjo Rivo Lucía González González Irene Rodríguez Conde María Fernández Soneira Javier Posada García Javier de la Fuente Aguado
author_facet	Jose Luis Lamas Ferreiro Judith Álvarez Otero Ana Sanjurjo Rivo Lucía González González Irene Rodríguez Conde María Fernández Soneira Javier Posada García Javier de la Fuente Aguado
author_sort	Jose Luis Lamas Ferreiro
title	Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection
title_short	Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection
title_full	Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection
title_fullStr	Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection
title_full_unstemmed	Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection
title_sort	outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with pseudomonas aeruginosa infection
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2e67001240094fa9a004bb7c9c0b0b1a
work_keys_str_mv	AT joseluislamasferreiro outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection AT judithalvarezotero outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection AT anasanjurjorivo outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection AT luciagonzalezgonzalez outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection AT irenerodriguezconde outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection AT mariafernandezsoneira outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection AT javierposadagarcia outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection AT javierdelafuenteaguado outpatienttherapywithpiperacillintazobactamusingelastomericpumpsinpatientswithpseudomonasaeruginosainfection
_version_	1718380110473592832

Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection

Ejemplares similares